Compositions used and methods are disclosed for regulation of homeostasis of host cortisol and improving sleep quality including a composition derived from enriched for one or more phenylpropanoid acids and benzoxazinoids or extracts that are enriched for one or more phenylpropanoid acids and benzoxazinoids. Compositions of enriched for one or more phenylpropanoid acids and benzoxazinoids maintain homeostasis of host stress hormone, cortisol, selectively binds to MT2 over MT1 receptor, improves sleep quality by enhancing the deep sleep stage of sleep, increases total sleep time and deep sleep time, improves overall mental well-being measured by the Pittsburgh Sleep Quality Index (PSQI) and Profile of Mood States (POMS), provides positive mood support and enhances emotional well-being; maintains homeostasis of biomarkers—serotonin, melatonin, GABA in formulation in a mammal disclosed that includes administering an effective amount of a composition from 0.01 mg/kg to 1000 mg/kg body weight of the mammal.

A method for production of red ginseng hydrolysis concentrate according to an embodiment of the present disclosure includes carrying out an enzyme reaction of red ginseng concentrate by adding an enzyme solution followed by addition of alcohol to prepare a mixture solution of red ginseng and alcohol, and centrifuging the prepared mixture solution of red ginseng and alcohol followed by concentration under reduced pressure of a supernatant separated by the centrifuge, and a red ginseng hydrolysis concentrate produced by the aforementioned process.

A method for production of red ginseng hydrolysis concentrate according to an embodiment of the present disclosure includes carrying out an enzyme reaction of red ginseng concentrate by adding an enzyme solution followed by addition of alcohol to prepare a mixture solution of red ginseng and alcohol, and centrifuging the prepared mixture solution of red ginseng and alcohol followed by concentration under reduced pressure of a supernatant separated by the centrifuge, and a red ginseng hydrolysis concentrate produced by the aforementioned process.

A method for production of red ginseng hydrolysis concentrate according to an embodiment of the present disclosure includes carrying out an enzyme reaction of red ginseng concentrate by adding an enzyme solution followed by addition of alcohol to prepare a mixture solution of red ginseng and alcohol, and centrifuging the prepared mixture solution of red ginseng and alcohol followed by concentration under reduced pressure of a supernatant separated by the centrifuge, and a red ginseng hydrolysis concentrate produced by the aforementioned process.

A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

An improved plant medicament composition, comprising an extract of Sorghum bicolor plant material for treating sickle cell disease is described. A method for the preparation of said composition having the property of inhibiting sickle cells is also provided.

An improved plant medicament composition, comprising an extract of Sorghum bicolor plant material for treating sickle cell disease is described. A method for the preparation of said composition having the property of inhibiting sickle cells is also provided.

Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.